Developing new medicines or demonstrating the equivalence of generic products involves the coordination of multiple specialized activities, including study design, regulatory preparation, clinical execution, bioanalysis, and pharmacokinetic evaluation. In many cases, these activities are performed by different providers, requiring sponsors to coordinate several vendors throughout the study lifecycle. This causes operational complexity and may affect timelines, communication, and overall study efficiency.
Integrated service models can help address these challenges by centralizing study coordination and scientific expertise. Within this framework, a single organization supervises the different stages of the study while working with specialized partners when required. This integrated approach combines scientific work, operational efficiency, and regulatory compliance to support the entire study lifecycle.
In this article you will learn how integrated study support can facilitate and speed development programs, and we will share how this one-stop solution is implemented at Kymos Group.
An Integrated Approach to Study Management
Complex studies often require coordination between multiple partners, including sponsors, clinical or animal study sites, analytical laboratories, and regulatory organizations. Ensuring that these activities remain aligned throughout the project is essential for maintaining study quality and timelines.
Study planning typically begins with a consultation phase in which scientific and operational aspects are defined. Study objectives, regulatory requirements, timelines, and analytical needs are evaluated to establish an appropriate strategy for the program.
Based on this information, a study framework can be developed to coordinate the activities of the different stakeholders involved. Centralized supervision helps facilitate communication, reduce operational complexity, and maintain consistency throughout the study.
At Kymos Group, this type of integrated project management is applied to support both regulated studies conducted under Good Laboratory Practice (GLP) and Good Clinical Practice (GCP), as well as non-regulated exploratory programs at earlier stages of development.
Comprehensive Bioequivalence Study Management
Bioequivalence studies require close coordination between clinical operations, analytical laboratories, and regulatory activities. Careful planning is essential to ensure that study design, sample management, and analytical methods are aligned with regulatory expectations.
Study management therefore typically includes several stages, beginning with study preparation and regulatory activities. At Kymos Group, these activities are coordinated together with specialized partners and clinical sites to ensure efficient study execution. This typically includes:
Study preparation and regulatory activities
- Study design and protocol writing
- Submission to Ethics Committees and Health Authorities
- IMPD writing or review
- Insurance contracting
Clinical study coordination
- Clinical center management and monitoring
- Bioequivalence study execution
- Central laboratory coordination
- Pharmacovigilance support
Study completion
- Preparation of the final clinical report
- Support for responses to regulatory authority requests
Coordinating these activities under a single project structure helps maintain consistency throughout the study and simplifies communication between all parties involved.
Operational and Logistical Support
The successful execution of clinical and preclinical studies depends not only on scientific expertise but also on effective operational and logistical organization. Study materials, reference products, analytical samples, and clinical supplies must be managed under controlled conditions and within strict timelines.
Several complementary services are typically required to support these activities, including:
- Procurement of reference medications
- Importation of reference and test products
- Comparative dissolution profile studies
- Batch testing and batch release
- Stability testing and analytical support
- Physical-chemical characterization of formulations
- Sample storage and biobanking
- Clinical kitting services and collection set preparation
At Kymos Group, these operational activities are coordinated together with analytical and study management teams to ensure that materials, samples, and documentation remain aligned throughout the study.
Sample management is also a critical component of many studies. Labeling, shipment, and storage procedures must ensure full traceability while preserving sample integrity throughout the study lifecycle.
Bioanalytical Expertise Built on Decades of Experience
Bioanalysis plays a central role in many research programs, as the accurate quantification of compounds in biological matrices is essential for pharmacokinetic evaluation and regulatory submissions.
The development and validation of bioanalytical methods require specialized expertise and advanced analytical technologies. These methods must meet strict regulatory requirements while providing reliable and reproducible data across different biological matrices.
At Kymos Group, bioanalysis represents a core area of expertise. With more than two decades of experience in the development, validation, and application of bioanalytical methods, our company supports studies involving both small molecules, TIDES and biologics.
Laboratories in Barcelona (Spain) and Frankfurt (Germany) are equipped with advanced analytical platforms and supported by experienced scientific teams capable of analyzing a wide range of compounds.
Pharmacokinetic Evaluation and Data Analysis
Once bioanalytical data have been generated, pharmacokinetic and statistical evaluation becomes essential for interpreting study results. These analyses allow the characterization of drug exposure, variability, and equivalence between formulations.
At Kymos Group, pharmacokinetic evaluations are performed using widely recognized platforms such as Phoenix WinNonlin, commonly used for pharmacokinetic and bioequivalence analysis.
Typical activities include:
- Pharmacokinetic parameter calculation
- Statistical analysis for bioequivalence evaluation
- Preparation of comprehensive pharmacokinetic reports
These analyses provide reliable data to support scientific decision-making and regulatory submissions.
Strategic Partnerships and Study Expertise
As previously mentioned, the execution of complex research programs involves collaboration between multiple specialized organizations. Long-standing partnerships between analytical laboratories, clinical centers, and research facilities make it possible to support a wide variety of study types while maintaining high quality standards.
Through its network of trusted partners, Kymos Group can support studies across clinical, preclinical, and veterinary research environments while maintaining centralized scientific and project oversight.
Examples of studies that can be supported include:
Preclinical and Animal Health
- Pharmacokinetics, bioavailability, tolerance, and efficacy studies
- Toxicity studies and customized protocols
- Veterinary and residue depletion studies
- Full support with bioanalysis, diagnostics, and pathology
- Reports recognized by major regulatory authorities
Clinical Studies
- Phase I and Proof-of-Concept studies
- First-in-Human dose escalation studies
- PK/PD, drug-drug interaction, food-effect, and QT/QTc studies
- Bioavailability and bioequivalence studies
- Studies in special populations
The integration of study execution, laboratory analysis, and centralized project management ensures continuous oversight and seamless coordination across all activities.
One-Stop-Shop Solution for Biosimilar Development
- Analytical comparability and CMC biosimilarity studies
- PK/PD and immunogenicity assessment (ADA/NAb)
- GLP-compliant bioanalytical support and regulatory-aligned documentation
Conclusion
The development of new medicines and generic products requires the coordination of numerous scientific, clinical, and operational activities. Managing these components efficiently is often critical for maintaining study timelines and ensuring data reliability.
Integrated study models as one-stop solutions provide a practical solution by bringing together analytical expertise, clinical execution, and project management within a coordinated framework.
At Kymos Group, this approach combines bioanalytical capabilities, study management experience, and collaboration with specialized partners to support bioequivalence, clinical, preclinical, and animal health programs from early planning through to final reporting.
For further information on our one-stop solution capabilities or support for your studies, feel free to contact our team at https://kymos.com/contact/ or commercial@kymos.com
